Correction to: Saratale et al. Significance of Immune Status of SARS-CoV-2 Infected Patients in Determining the Efficacy of Therapeutic Interventions. J. Pers. Med. 2022, 12, 349

Ganesh Dattatraya Saratale, Han Seung Shin, Surendra Krushna Shinde, Dae Young Kim, Rijuta Ganesh Saratale, Avinash Ashok Kadam, Manu Kumar, Ali Hassan Bahkali, Asad Syed, Gajanan Sampatrao Ghodake

Research output: Contribution to journalComment/debate

Abstract

Errors in Figures and Table Caption In the original publication [1], there were mistakes in the legends for Figure 1, Figure 2, and Table 1. We failed to mention the citation number in these legends. The correct legends appear below. Figure 1. Emerging therapeutic approaches against COVID-19 disease: (1) antibodybased therapeutics against the S protein (either via adoptive transfer of vaccination) to avoid progression of severe infections; (2) application of protease inhibitors against serine protease (TMPRSS2) prevents cleavage of S protein; (3) SRS-CoV-2 virus-specific memory CD8+ T cells from vaccination or earlier infection; (4) a new treatment approach targets the symptoms of cytokine storm, wherein the blood of infected patients is passed through customized filtration columns to capture pro-inflammatory cytokines before the pureblood returns to patients. Adapted and modified from [63]. Figure 2. Cytokine pathogenesis of SARS-CoV-2 infection. Intensive care or appropriate treatment is recommended for hospitalized severe SARS-CoV-2 patients who exhibit elevated levels of biomarkers in blood plasma: alveolar cell (AC), angiotensin-converting enzyme 2 (ACE2), atopic dermatitis (AD), ancestry clusters (AC1-4) granulocyte-macrophage colony–stimulating factor (GM–CSF), granulocyte colony–stimulating factor (G–CSF or GCSF), interleukin (IL), interferon (INF), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory proteins (MIP1), natural killer (NK), polymorphonuclear granulocyte (PMN), T-effector cell (TEFF cell), tumor necrosis factor (TNF), regulatory T cell (Treg cell). Adapted and modified from [116]. Table 1. Mechanism of types of drugs and therapies useful in the treatment of SARSCoV- 2-infected patients [3,27,32]. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. These corrections were approved by the Academic Editor. The original publication has also been updated.

Original languageEnglish
Article number967
JournalJournal of Personalized Medicine
Volume12
Issue number6
DOIs
StatePublished - Jun 2022

Fingerprint

Dive into the research topics of 'Correction to: Saratale et al. Significance of Immune Status of SARS-CoV-2 Infected Patients in Determining the Efficacy of Therapeutic Interventions. J. Pers. Med. 2022, 12, 349'. Together they form a unique fingerprint.

Cite this